Searched for
REVISED CLINICAL GUIDANCE
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- Kerala Budget 2026-27: Govt eyes assembly polls, announces various people-centric schemesKerala's Finance Minister K N Balagopal unveiled a budget for 2026-27. It promises a Rs 14,500 crore boost for pensioners and community pro...
- Revised rules for biosimilar drugs enter the final stretchThe Indian government is refining biosimilar drug regulations, aligning with global standards to ensure stringent quality in research and m...
- IBA chief explains what bank frauds really are, stresses on critical 'golden hour'As per the RBI's recent annual report, fraud cases surged to 36,075 in FY24, marking a significant rise from 13,564 reported in the previou...
- New COVID-19 treatment guidelines: Antibiotics only for bacterial infections, says CentreThe guidelines recommend the use of Remdesivir for up to five days in moderate or severe cases with a high risk of progression, and only fo...
- Omicron is dominant COVID-19 variant in country: GovtWith the reporting of Omicron, a highly mutated variant of SARSCoV-2 virus and its classification as a Variant of Concern (VoC) by the Worl...
- Go for test for TB, other conditions if cough persists for more than 2-3 weeks: Revised clinical guidance for Covid patientsThe revised guidelines continue to recommend emergency use authorization (EUA) or off-label use of remdesivir in patients with "moderate to...
- ICMR national protocol says no evidence of benefit of injectable steroids in patients not requiring oxygenThe revised guidance updated on January 14 also warns of potential risk of fungal infections such as invasive mucormycosis, if anti-inflamm...
- Covid treatment: Govt issues revised guidelines on use of drugs, therapiesThe revised guidelines continue to recommend emergency use authorization (EUA) or off-label use of remdesivir in patients with "moderate to...
- Mansukh Mandaviya launches 6th edition of National Formulary of India to promote rational use of medicinesMandaviya said that the NFI 2021 would act as a guidance document for all the healthcare professionals such as clinicians, pharmacists, nur...
- HCQ out of DGHS Covid care list, but still present in ICMR protocolIndian Council for Medical Research (ICMR), the country’s leading health research body, however, has not yet revised its clinical guidance ...
- Bharat Biotech needs to give phase-3 efficacy data for WHO nodInclusion in the EUL is also important for easy international travel of Indian citizens who have been administered Covaxin.
- India drops plasma therapy from COVID-19 management guidelinesExperts at the ICMR had been reviewing the available data and had not found any benefit. “The recovery trial document was examined and show...
- Govt revises policy for admission of patients in hospitals, says positive Covid test not requiredNo patient shall be refused admission on the ground that he/she is not able to produce a valid identity card that does not belong to the ci...
- SEC recommends Bharat Biotech’s Covaxin for emergency useThe Drug Controller General of India (DCGI) will give the final approval to both the vaccine candidates.
- Divide among experts may force ICMR to revise HCQ guidelinesWith some microbiologists opposing the use of HCQ for Covid-19, a debate is raging on among members of the task force over continuing with ...
- WHO announces important changes to multi drug resistant TB treatmentIn its last-issued guidance in October 2016, the WHO had restricted usage to the breakthrough drug owing to concerns around its effect on t...
- Sanofi continues to seek clinical trial waiver in India for controversial dengue vaccinePhase 3 trials are the last phase of clinical trials that a company conducts before it receives approval to market the drug here.
- Sun Pharma hits 44-month low, down 24% in 7 sessions; what experts sayThe stock fell 12.84 per cent to hit a 44-month low of Rs 495.55 amid weak fourth quarter results.
- Nicholas's NCE pipeline at Rs 1000-1300 cr: EmkayEmkay Research is positive on the developments and business of Nicholas Piramal Ltd though it has not made any formal rating on the stock.
Load More
